- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 2,001 of 2,219.
| EudraCT Number: 2011-004823-11 | Sponsor Protocol Number: remifentanil2011 | Start Date*: 2012-08-03 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
| Full Title: Randomized prospective multicenter study on remifentanil analgesic efficacy in labor: intermittent intravenous infusion administration vs continuous intravenous infusion | |||||||||||||
| Medical condition: women during labor | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-003036-31 | Sponsor Protocol Number: 01B | Start Date*: 2012-03-20 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
| Full Title: Ministry of health integrated oncological program n°5/2006: 18F-Fluorometilcholine (18FFCH) PET/CT sensibility in diagnosis of breast cancer metastasis | |||||||||||||
| Medical condition: de novo breast cancer metastasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000513-48 | Sponsor Protocol Number: RCMM2015 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI | |||||||||||||
| Full Title: Safety and efficacy of the inhalation of bicarbonate in patients with cystic fibrosis | |||||||||||||
| Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002182-35 | Sponsor Protocol Number: buspirone2019 | Start Date*: 2019-09-10 |
| Sponsor Name:KU Leuven - TARGID | ||
| Full Title: The effect of oral buspirone hydrochloride on esophageal motility, bolus transit and symptoms of dysphagia, in patients with poor esophageal motility: A randomized, double-blind, placebo controlle... | ||
| Medical condition: Patients with complaints of dysphagia and poor esophageal motility | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004545-18 | Sponsor Protocol Number: NA | Start Date*: 2005-04-26 |
| Sponsor Name:CHU Sart Tilman | ||
| Full Title: Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy. | ||
| Medical condition: Chronic ischemic cardiac disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-005210-20 | Sponsor Protocol Number: 2005-005210-20 | Start Date*: 2006-04-10 |
| Sponsor Name:CHU Sart-Tilman | ||
| Full Title: Phase II trial of caspofungin as secondary prophylaxis for invasive fungal infections in patients with high-risk hematological malignancies undergoing intensive chemotherapy or hematopoietic stem ... | ||
| Medical condition: Acute leukemia during induction or consolidation therapy. Autologous HSCT for a hematological malignancy. Standard allogeneic HSCT with a myeloablative conditioning regimen. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004101-26 | Sponsor Protocol Number: TJB0601P1 | Start Date*: 2006-12-13 | |||||||||||
| Sponsor Name:CHU Sart-Tilman | |||||||||||||
| Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study | |||||||||||||
| Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities. | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-005966-39 | Sponsor Protocol Number: TJT1123 | Start Date*: 2012-03-08 | ||||||||||||||||||||||||||
| Sponsor Name:CHU-ULg | ||||||||||||||||||||||||||||
| Full Title: Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders. | ||||||||||||||||||||||||||||
| Medical condition: Crohn's disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2007-004310-14 | Sponsor Protocol Number: TJB0703 | Start Date*: 2007-12-13 | |||||||||||||||||||||
| Sponsor Name:CHU-ULG | |||||||||||||||||||||||
| Full Title: Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study | |||||||||||||||||||||||
| Medical condition: Steroid resistant grade II to IV acute graft-versus-host disease (GVHD) or poor graft function after allogeneic hematopoietic cell transplantation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-004169-28 | Sponsor Protocol Number: SC17.02 | Start Date*: 2018-06-21 | |||||||||||
| Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA | |||||||||||||
| Full Title: Augmentation versus switch: comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression | |||||||||||||
| Medical condition: Non-responders with Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002102-58 | Sponsor Protocol Number: TJT2012 | Start Date*: 2020-06-12 | |||||||||||
| Sponsor Name:CHU de Liège | |||||||||||||
| Full Title: Mesenchymal stromal cell therapy for severe COVID-19 infection | |||||||||||||
| Medical condition: Patients with severe COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003275-30 | Sponsor Protocol Number: 011-IRCC-10IIS-15 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS | |||||||||||||
| Full Title: Open-label, phase ii study of trastuzumab emtansine in patients with HER2-positive metastatic colorectal cancer progressing after trastuzumab and lapatinib: (HER2 Amplification for Colo-rectaL canc... | |||||||||||||
| Medical condition: metatastatic colorectal carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000944-41 | Sponsor Protocol Number: FenS-FenD | Start Date*: 2015-04-20 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: A PILOT STUDY TO TEST THE FEASIBILITY OF A TWO-ARM, DOUBLE BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED TRIAL FOR THE COMPARISON OF THE DURATION OF THE ANALGESIC EFFICACY OF A SINGLE MATRIX TRANSDE... | |||||||||||||
| Medical condition: Patients with oncological pain | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003505-26 | Sponsor Protocol Number: TOHNER/31 | Start Date*: 2019-03-18 | |||||||||||
| Sponsor Name:ABIOGEN PHARMA S.P.A. | |||||||||||||
| Full Title: Randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of treatment with Neridronate 100 mg (4 infusions over a period of 10 days) in patients with tra... | |||||||||||||
| Medical condition: Transient osteoporosis of the hip. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002239-41 | Sponsor Protocol Number: SC17.01 | Start Date*: 2018-02-16 | |||||||||||
| Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA | |||||||||||||
| Full Title: Effects of Safinamide therapy on reuroplasticity in patients with Parkinson's disease | |||||||||||||
| Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001478-27 | Sponsor Protocol Number: IRFMN-GCC-7813 | Start Date*: 2019-09-11 | |||||||||||
| Sponsor Name:Associazione Chirurghi Ospedalieri Italiani | |||||||||||||
| Full Title: Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcomes.... | |||||||||||||
| Medical condition: Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004946-41 | Sponsor Protocol Number: SP-PP18 | Start Date*: 2019-09-12 |
| Sponsor Name:Dr. Virgilio P. Carnielli, | ||
| Full Title: Personalized versus standard parenteral nutrition for preterm infants with a birth weight greater than 1250 grams: a phase IV randomized clinical trial | ||
| Medical condition: Growth of preterm infants with a birth weight greater than 1250g on parenteral nutrition. | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000261-36 | Sponsor Protocol Number: 1.0 | Start Date*: 2021-01-27 | |||||||||||
| Sponsor Name:Holostem Terapie Avanzate s.r.l. | |||||||||||||
| Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRINCULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED F... | |||||||||||||
| Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001437-14 | Sponsor Protocol Number: IRFMN-CRC-7813 | Start Date*: 2019-09-11 | |||||||||||
| Sponsor Name:Associazione Chirurghi Ospedalieri Italiani | |||||||||||||
| Full Title: Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcom... | |||||||||||||
| Medical condition: patients with colorectal carcinoma at high risk peritoneal carcinomatosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002172-39 | Sponsor Protocol Number: VX21-CTX001-141 | Start Date*: 2021-10-05 | |||||||||||
| Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED | |||||||||||||
| Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia | |||||||||||||
| Medical condition: Transfusion-Dependent ß Thalassemia | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.